Drug intelligence / Profile preview

oral uricase

Development stage: Preclinical
Lead developer: Matwings Technology
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

Oral uricase is an oral biologic enzyme therapy being developed by Matwings for the treatment of hyperuricemia. The drug is designed to enzymatically degrade uric acid within the gastrointestinal tract, thereby reducing systemic blood uric acid levels. A significant technical feature of this program is its six-fold improved stability in the small intestine compared to conventional uricase formulations. In preclinical models, the therapy demonstrated a 54.4% reduction in blood uric acid in mice and a 39.6% reduction in rats. The program aims to provide a non-invasive, oral alternative to injectable uricase therapies for managing chronic gout and other hyperuricemic conditions.

Other names: 口服尿酸酶

Beyond the preview

Go deeper on oral uricase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oral uricase.

Explore the full profile